Results 251 to 260 of about 38,385 (346)

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer   +6 more
wiley   +1 more source

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen   +12 more
wiley   +1 more source

Independent associations of mental health and diabetes complications with health‐related quality of life: Evidence from a cross‐sectional study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Health‐related quality of life (HRQoL) is a key patient‐reported outcome in diabetes care, yet the extent to which somatic and psychological factors are associated with HRQoL remains unclear. This study examined how demographic, diabetes‐related, medical, and psychological factors were independently associated with HRQoL in adults with ...
Norbert Hermanns   +4 more
wiley   +1 more source

Pathologic and Therapeutic Schwann Cells. [PDF]

open access: yesCells
Shurin MR, Wheeler SE, Zhong H, Zhou Y.
europepmc   +1 more source

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong   +3 more
wiley   +1 more source

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy